Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuroendocrine Breast Tumor
- Neuroendocrine Carcinoma Metastatic
- Neuroendocrine Neoplasm of Ovary
- Neuroendocrine Skin Carcinoma
- Neuroendocrine Tumors
- Paraganglioma
- Pheochromocytoma
- Pulmonary Neuroendocrine Neoplasm
- Thymus Carcinoid
- Unknown Primary Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04276597
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ebrahim Delpassand, MD Excel Diagnostics and Nuclear Oncology Center Study Director: Rodolfo Nunez, MD Excel Diagnostics and Nuclear Oncology Center Study Director: Afshin Shafie, MD Excel Diagnostics and Nuclear Oncology Center Study Director: Ayman Gaber, MD Excel Diagnostics and Nuclear Oncology Center
Get Well Soon